lithium perchlorate

This chemical does not meet GHS hazard criteria for 0.5% (1 of 192) of reports.

H271 (69.8%): May cause fire or explosion; strong Oxidizer [Danger Oxidizing liquids; Oxidizing solids]

H272 (27.6%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]

H302 (59.9%): Harmful if swallowed [Warning Acute toxicity, oral]

H314 (56.2%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]

H315 (26%): Causes skin irritation [Warning Skin corrosion/irritation]

H318 (56.2%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

H319 (26%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

H335 (26.6%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

H373 (54.7%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

P210, P220, P260, P261, P264, P264+P265, P270, P271, P280, P283, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P306+P360, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P370+P378, P371+P380+P375, P403+P233, P405, P420, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 192 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Reported as not meeting GHS hazard criteria per 1 of 192 reports by companies.

There are 14 notifications provided by 191 of 192 reports by companies with hazard statement code(s).

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

1.2 [mg/m3]

13 [mg/m3]

79 [mg/m3]

Chronic Oral: 0.0007 mg/kg/day (L900)

Colorless deliquescent solid; [Hawley] Colorless or white odorless solid; Hygroscopic; [CHEMINFO] White lumps; [MSDSonline] Crystallizes from solution as the trihydrate; Converts to the anhydrous form at 130-150 deg C; [Ullmann]

Other Classes -> Perchlorates

CSL00084

DIETHYL ETHER + LITHIUM PERCHLORATE

refluxing led to an explosion

Explosive

User-Reported

The primary and most sensitive target of the perchlorate anion (perchlorate) is the thyroid gland. Perchlorate inhibits the transport of iodide (I-) from the blood into the thyroid follicle cells. The inhibition is thought to be accomplished by perchlorate competitively blocking iodide binding to a carrier, or sodium/iodide symporter (NIS), which catalyzes the simultaneous transfer of Na+ and I-across the basolateral membrane of thyroid follicle cells. Perchlorate inhibition of the NIS can limit the availability of iodide needed for the production of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), which in turn, may affect the circulating levels of T4 and T3. All known effects of perchlorate on the thyroid hormone system derive directly or secondarily from the inhibition of the NIS. T3 is essential for normal development of the nervous system and for the regulation of metabolism of cells in nearly all tissues of the body. Disruption in the availability of T3 in target tissues can result in adverse effects on a wide variety of organs and systems (L894).

No indication of carcinogenicity to humans (not listed by IARC).

Adverse effects on a wide variety of organ systems can result from disruption in the availability of T3 to target tissues. Organ systems affected by disturbances in T3 levels include the skin, cardiovascular system, pulmonary system, kidneys, gastrointestinal tract, liver, blood, neuromuscular system, central nervous system, skeleton, male and female reproductive systems, and numerous endocrine organs, including the pituitary and adrenal glands. Such an array of secondary potential targets underscores the need to maintain an adequate level of circulating thyroid hormones. Perchlorate, an environmental contaminant, is known to disturb the hypothalamus-pituitary-thyroid (HPT) axis by blocking iodide accumulation in the thyroid. Iodide deficiency can lead to hypothyroidism and goiter (L894, A267).

Inhalation (L894) ; oral (L894) ; dermal (L894) ; eye contact (L894).

Irritating to skin, eyes, and respiratory system, depending on the route of exposure. Esophageal or gastrointestinal tract irritation could occur following exposures (L894).

Neurotoxin - Other CNS neurotoxin

Nephrotoxin - The chemical is potentially toxic to the kidneys in the occupational setting.

Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect

IRIS Current

In case of oral exposure, immediately dilute with 4 to 8 ounces (120 to 240 mol) of water or milk. Consider after ingestion of a potentially life-threatening amount of poison if it can be performed soon after ingestion (generally within 1 hour). Protect airway by placement in Trendelenburg and left lateral decubitus position or by endotracheal intubation. Control any seizures first. Maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry monitoring. Early use of PEEP and mechanical ventilation may be needed. Following inhalation, Move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with inhaled beta2 agonist and oral or parenteral corticosteroids. In case of acute lung injury, maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry monitoring. Following eye exposure, irrigate exposed eyes with copious amounts of room temperature water for at least 15 minutes. Following dermal exposure, remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician may need to examine the area if irritation or pain persists. Treat dermal irritation or burns with standard topical therapy. Patients developing dermal hypersensitivity reactions may require treatment with systemic or topical corticosteroids or antihistamines. (T36)

5.50e+01

8.20e+02

1.40e+01

4.00e-03

7.00e-04

Volatile

1.60e+02

2.50e+03

4.20e+01

5.50e+01

8.20e+02

1.40e+01

4.00e-03

7.00e-04

Volatile

1.60e+02

2.50e+03

4.20e+01